New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30
September 2013 amounts to 270,389,770 shares, whereof 265,226,598 common shares
and 5,163,172 class C shares, corresponding to in total 265,742,915.2 votes. The
increase in the number of shares and votes results from an issue of 754,912
class C shares under Swedish Orphan Biovitrum's incentive program. The class C
shares are intended to ensure fulfillment of commitments under incentive
programs. The company holds all 5,163,172 class C shares.

---

About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com.

 For more information -
 not for publication

 Media relations           Investor relations

 Oskar Bosson, Head of     Jörgen Winroth, Vice President, Head of Investor
 Communications            Relations

 T: +46 70 410 71 80       T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135

 oskar.bosson@sobi.com     jorgen.winroth@sobi.com


The above information has been made public in accordance with the Swedish
Securities Market Act and/or the Financial Instruments Trading Act. The
information was released for public distribution on 1 October 2013 at 08:30 CET.


[HUG#1732610]